Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Preparing word cloud

×

Search

Type in a keyword to search

Filter by last modified time
See new records

Current Facets and Filters

  • Relation:listed by: Consortia-pedia (facet)
  • Website Status : Ascending

Facets

Sort alphabetically | Sort by count

Recent searches

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

(last updated: Sep 3, 2019)

Physical Resource or Software Tool Software

80 Results - per page

Resource NameResource TypeDescriptionKeywordsResource IDProper CitationParent OrganizationRelated ConditionFunding AgencyRelationReferenceWebsite StatusAlternate IDsAlternate URLsOld URLs
CAMDResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceA consortium developing new technologies and methods to accelerate the development and review of medical products for neurodegenerative diseases. It is focused on accelerating drug development for patients with chronic neurodegenerative disease, namely, Alzheimer's disease (AD) and Parkinson's disease (PD), by advancing drug development tools for evaluating drug efficacy, conducting clinical trials, and streamlining the process of regulatory review. The consortium focuses on sharing precompetitive patient-level data from the control arms of legacy clinical trials, developing new tools to be submitted to the regulatory agencies, and developing consensus data standards. CAMD has the following areas of focus: (1) qualification of biomarkers, (2) development of common data standards, (3) creation of integrated databases for clinical trials data, and (4) development of quantitative model-based tools for drug development. Regulatory milestones include a qualification opinion with EMA for the use of low baseline hippocampal volume for patient enrichment in pre-dementia trials, and most recently, positive regulatory decisions from the FDA and EMA for the use of a clinical trial simulation tool to aid in trials for mild to moderate stages of AD.data set, clinical trial, mild cognitive impairment, clinical, biomarker, metadata standard, disease progression model, consortium, drug, data sharing, disease modeling, drug development, disease model, imaging, cerebral spinal fluidSCR_001389(CAMD, RRID:SCR_001389)Critical Path Institute; Arizona; USA Publicly fundedlisted by: Consortia-pediaLast checked downnlx_152563
MMRF CoMMpass StudyResource, disease-related portal, topical portal, organization portal, consortium, portal, data or information resourceA personalized medicine initiative to discover biomarkers that can better define the biological basis of multiple myeloma to help stratify patients. This effort hopes to obtain samples from approximately 1,000 multiple myeloma patients and follow them over time to identify how a patient's genetic profile is related to clinical progression and treatment response. As a partnership between 17 academic centers, 5 pharmaceuticals and the Department of Veterans Affairs, the goal of this eight year study is to create a database that can accelerate future clinical trials and personalized treatment strategies. MMRF's CoMMpass Study has the following goals: * Create a guide to which treatments work best for specific patient subgroups. * Share data with researchers to accelerate drug development for specific subtypes of multiple myeloma patients. In order to facilitate discoveries and development related to targeted therapies, the comprehensive data from CoMMpass is placed in an open-access research portal. The data will be part of the Multiple Myeloma Research Foundation's (MMRF) Personalized Medicine Platform combines CoMMpass data with those collected from MMRF's Genomics Initiative. It is hoped that the longitudinal data, combined with the annotated bio-specimens will help provide insights that can accelerate personalized therapies.consortium, biomarker, molecular, genetic, blood, cancer, clinical, data sharingSCR_003721(MMRF CoMMpass Study, RRID:SCR_003721)Multiple Myeloma Research Foundation Multiple Myeloma Research Foundation, United States Department of Veterans Affairsuses: Multiple Myeloma Genomics Portal, listed by: Consortia-pediaLast checked downnlx_157899
California Integrated Data ExchangeResource, organization portal, portal, consortium, data or information resourceA three-year consortium that brings together insurers and health care providers to share information from approximately 9 million patients, with a goal that insights from the data will bring down healthcare costs and improve outcomes. It aims to be one of the largest health information exchanges in the country, with the goal of better connecting the vast, often disparate healthcare landscape across California. The database that will house patient data will be overseen by Orion Health, an independent eHealth software company. The information will only be used for clinical purposes. Academic research institutions can apply to use the Cal INDEX de-identified data for research to benefit the public good, such as population health initiatives. Cal INDEX has five main goals: * Improve the quality of care by providing clinicians with a unified statewide source of integrated patient information * Provide patients with a seamless transition between health plans or across various healthcare professionals and hospitals * Improve efficiency and reduce the cost of healthcare * Encourage healthcare technology innovation * Improve public health by providing de-identified data for medical research. Cal INDEX plans to launch at the end of 2014 with approximately 9 million health information records from combined members of Dignity Health and Blue Shield of California and Anthem Blue Cross. Cal INDEX is open to any health data contributor. Cal INDEX will establish a bi-directional data interface with providers to exchange data with EMRs and other hospital and office-based systems.healthcare, data sharing, tool development, consortium, health information exchange, health information, health, california, clinical, electronic patient record, database, de-identifiedSCR_003747(California Integrated Data Exchange, RRID:SCR_003747)Anthem Blue Cross, Blue Shield of Californialisted by: Consortia-pediaLast checked downnlx_157980
BioSHaREResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceA consortium of leading biobanks and international researchers from all domains of biobanking science to ensure the development of harmonized measures and standardized computing infrastructures enabling the effective pooling of data and key measures of life-style, social circumstances and environment, as well as critical sub-components of the phenotypes associated with common complex diseases. The overall aim is to build upon tools and methods available to achieve solutions for researchers to use pooled data from different cohort and biobank studies. This, in order to obtain the very large sample sizes needed to investigate current questions in multifactorial diseases, notably on gene-environment interactions. This aim will be achieved through the development of harmonization and standardization tools, implementation of these tools and demonstration of their applicability. BioSHaRE researchers are collaborating with P3G, the Global Alliance for Genomics and Health, IRDiRC (International Rare Diseases Research Consortium), H3Africa and other organizations on the development of an International Code of Conduct for Genomic and Health-Related Data Sharing. A draft version is available for external review. Generic documents have been prepared covering areas of biobanking that are of major importance. SOPs have been finalized for blood withdrawal (SOPWP5001blood withdrawal), manual blood processing (SOPWP5002blood processing), shipping of biosamples (SOPWP5003shipping) and withdrawal, processing and storage of urine samples (SOPWP5004urine).gene-environment interaction, life-style, social circumstance, environment, phenotype, disease, biobank, socio-economic factor, data sharing, gene, clinicalSCR_003811(BioSHaRE, RRID:SCR_003811)University of Groningen; Groningen; Netherlands European Union FP7listed by: Consortia-pediaLast checked downnlx_158110
AtheroRemoResource, organization portal, portal, consortium, data or information resourceProject targeting vulnerable plaques causing unexpected acute myocardial infarcts and sudden cardiac deaths by identifying and validating novel drug targets as well as devising and validating diagnostic tests. It has been designed to advance the present knowledge on the role of inflammatory remodeling in the different stages of atherosclerosis. It will also provide important knowledge for the development of strategies for prevention and clinical management of vascular diseases.consortium, drug target, diagnostic test, clinical, plaque, inflammation, functional genomics, target validation, lipidomicsSCR_003831(AtheroRemo, RRID:SCR_003831)European Union FP7listed by: Consortia-pediaLast checked downnlx_158144
CALLIOPE NetworkResource, organization portal, portal, consortium, data or information resourceConsortium to act as a forum for the diversity of stakeholders in the implementation of electronic health systems. It comprises a dedicated forum where decision makers, implementers, professionals, patients and other stakeholders can share visions, experiences and good practices on how to establish interoperable eHealth services. The process of consensus-building has reached six main achievements. # Offering support to European decision-makers with regard to EU level actions on eHealth. # Enlarging active representation of EU and European Free Trade Association (EFTA) activities. CALLIOPE established a roster of 22 national members in 2010 # Enlarging active involvement of European eHealth stakeholder organizations. # Developing and validating an open working method among stakeholders # Creating a working collaboration method between the appropriate eHealth large-scale pilot(s) and a wider range of Member States & and sta-keholders CALLepSO collaboration # Building an eHealth Interoperability roadmapping process. A full iterative cycle of the Roadmapping process has been now completed and the second issue of the EU eHealth Interoperability Roadmap has been delivered.interoperability, ehealth, data sharing, healthcare, health, best practice, standardization, electronic health systemSCR_003845(CALLIOPE Network, RRID:SCR_003845)Competitiveness and Innovations Policy Support Programme, European Union FP6listed by: Consortia-pediaLast checked downnlx_158158
European Lead FactoryResource, organization portal, portal, consortium, data or information resourceConsortium that promotes the discovery of novel small molecule candidates suitable for subsequent optimization either to drug candidates or to high-quality pharmacological tools for the experimental validation of targets using open innovation and crowd sourcing. It is designed to provide best-in-class resources and funding-in-kind, to academics or small and medium enterprises (SMEs) who are working on promising biology targets or chemistry scaffolds. Screening of compounds to assess their activity is also funded and performed by the EU Lead Factory, with collaboration to help develop an Improved Hit List from the Qualified Hit List. They will provide collaborative screening of previously safeguarded, high quality corporate compounds. Around 300,000 compounds in the EFPIA Compound Collection, contributed by EFPIA members, will be screened against both commercially contributed biology targets and targets from public sources. The second phase of the consortium is to build a substantial new Public Compound Collection of around 200,000 compounds. Together, the EFPIA and Public compound collections will form a 500,000-strong Joint European Compound Collection. Target program owners and compound contributors will receive a Qualified Hit List (QHL) of up to 50 compounds complete with relevant information to help in the development of an Improved Hit List (IHL). Target program owners, will have exclusive access to threshold active compounds in their QHL. After the three-year exclusivity period, QHL/IHL information will be made public. Milestone payments are due if direct exploitation proceeds, not for research use. And owners and contributors will give EFPIA participants the right to submit a first bid (which they do not have to accept).drug, crowd sourcing, drug candidate, pharmacological tool, target, oncology, drug discovery, drug development, lead structure, lead, compound, lead molecule, tool development, biomarker, small molecule, basic science, screeningSCR_003858(European Lead Factory, RRID:SCR_003858)TI Pharma , Taros EFPIA, Innovative Medicines Initiativerelated to: Janssen Research and Development, Merck, BioAscent, ChemAxon, Edelris, GABO:mi, Lead Discovery Center, Mercachem, Pivot Park Screening Centre, Sygnature Discovery, Syncom, Taros, University of Dundee College of Life Sciences, Scotland, United Kingdom, Leiden University, Leiden, Netherlands, Max Planck Institute of Molecular Physiology, Dortmund, Germany, Radboud University, Nijmegen, The Netherlands, University of Groningen, Groningen, Netherlands, Technical University of Denmark, Lyngby, Denmark, TI Pharma, University of Duisburg-Essen, North Rhine-Westphalia, Germany, University of Leeds, West Yorkshire, United Kingdom, University of Nottingham, Nottingham, United Kingdom, VU University, Amsterdam, Netherlands, listed by: Consortia-pediaLast checked downnlx_158182
Asian Cancer Research GroupResource, data set, organization portal, portal, consortium, data or information resourceAn independent, not-for-profit consortium to accelerate research, and improve treatment for patients affected with the most commonly-diagnosed cancers in Asia by generating a genomic data resource for the most prevalent cancers in Asia. ACRG is focusing its initial efforts on Asian liver, gastric and lung cancers. Goals * Generate comprehensive genomics data sets for Asia-prevalent cancers * Conduct all research under good clinical practices and in accordance with local laws * Uncover key mutations and pathways for developing targeted therapies * Discover molecular tumor classifiers for patient stratification * Discover prognostic markers to identify high-risk patients * Freely share resulting raw data with scientific community to empower researchers globally and enable development of new diagnostics and medicines * Publish data analysis results jointly in prominent scientific journals Over the next two years, Lilly, Merck and Pfizer have committed to create an extensive pharmacogenomic cancer database that will be composed of data from approximately 2,000 tissue samples from patients with lung and gastric cancer that will be made publicly available to researchers and, over time, further populated with clinical data from a longitudinal analysis of patients. Comparison of the contrasting genomic signatures of these cancers could inform new approaches to treatment. Lilly has assumed responsibility for ultimately providing the data to the research public through an open-source concept managed by Lilly''''s Singapore research site. Moreover, Lilly, Merck and Pfizer will each provide technical and intellectual expertise. One dataset can be found at http://gigadb.org/dataset/100034asia, genomics, drug discovery, liver, gastric, lung, database, whole genome-wide study, drug development, basic research, data sharing, drug, oncology, pharmacogenomic, tissue, clinical, longitudinalSCR_004001(Asian Cancer Research Group, RRID:SCR_004001)Merck Eli Lilly and Company, Merck, Pfizerrelated to: Merck, Pfizer Animal Genetics, BGI, Shenzhen, China, uses: Gene Expression Omnibus, GigaDB, listed by: Consortia-pediaLast checked downnlx_158412
EU-ADRResource, organization portal, portal, consortium, data or information resourceConsortium that created the capability to detect Adverse Drug Response (ADR) signals by creating the infrastructure for large-scale monitoring of drug safety using electronic health records (EHR). The platform leverages EHR''''s comprising demographics, drug use and clinical data of over 30 million patients from several European countries. Special attention was given to patient groups that are not routinely involved in clinical trials, for ethical or practical reasons (e.g. pregnant women, elderly people, people using many drugs simultaneously, and children). This project also studies and compares a number of different techniques that all aim to detect unexpected or disproportional rates of events. The algorithms that they studied originate not only from the field of (pharmaco)epidemiology, but also from fields such as bio-terrorism, machine learning, and classical signal detection. EU-ADR specific objectives are: To detect events, To relate these events to drugs, To develop hypothesis that explain adverse events, To detect adverse events earlier, and To avoid false positives. The web-based platform is available at https://bioinformatics.ua.pt/euadr/ EU-ADR has contributed to the ability to conduct better drug safety studies based on the re-use of healthcare data. By facilitating the early detection of adverse drug reactions, but also providing key information on populations at risk, potential drug interactions, potential underlying mechanisms and intervening pathways in adverse events, etc., the project will allow for improved and more complete information to be available for drug and healthcare delivery, leading to increased patient safety and its associated cost savings. The EU-ADR system can be considered as a complementary tool to already existing pharamcovigilance systems. Should the system be widespread in the long term, it has the potential to contribute to the development of future electronic health record systems, insofar as the expected benefits of these IT tools are only fully attainable when EHRs develop themselves in consistency, richness and formats that allow them to be subject of such tools. In anticipation, EU-ADR has been designed to be modular and scalable, so that different EHR databases (other than those participating in the Consortium) can be progressively enlisted in the future, adopt the software for data extraction and therefore become susceptible of exploitation by the system, for maximum global effect.adverse drug reaction, clinical, biomedical, drug safety, electronic health record, demographic, drug use, clinical data, late adult human, child, young human, pregnant, drug, adverse event, signal detection, drug development, data sharing, text mining, epidemiology, database, data set, data repository, text extraction softwareSCR_004028(EU-ADR, RRID:SCR_004028) University of Aveiro; Aveiro; Portugal , Mar Institute of Medical Research Foundation European Union FP7related to: Mar Institute of Medical Research Foundation, University of Aveiro, Aveiro, Portugal, listed by: Consortia-pediaLast checked downnlx_158456
ONE StudyResource, organization portal, portal, consortium, data or information resourceConsortium aiming to produce regulatory T cells that are compatible with a kidney transplant patient''''s immune system, as a measure to suppress the body''''s natural immune response against a transplanted organ. If successful, this approach will reduce a transplantation patient''''s life-long dependency on immune suppressing drugs, many of which are often associated with undesirable side effects and can limit the patient''''s daily routine. The consortium goals are to develop and conduct clinical trials of various immunoregulatory T-cell-based products in organ transplantation recipients, allowing a direct comparison of the safety, clinical practicality and therapeutic efficacy of each cell type. The central focus of the project is to: # Production and manufacture of distinct populations of hematopoietic immunoregulatory T cells # Comparatively study the tolerogenic characteristics of these regulatory cell types # Test these cell therapy products side by side in a clinical trial living donor renal transplant recipients The first workstream will work with different T regulatory cell, tolerogenic DC and suppressive macrophage cell products that are currently in development. In addition to these therapeutics, another goal of this workstream is to develop a cell tracking technology that assesses pharmacodynamics and pharmacokinetics of these cell-based therapies. The second workstream is focused on designing and conducting a cell therapy based clinical trial in renal transplantation, taking into consideration ethics, concurrent immunosuppressive drug use, state-of-the-art immune monitoring, innovative all-in-one data capturing systems, and pharmacovigilance. The goal is to have a comparative evaluation of hematopoietic cell therapy safety in renal transplantation. The third workstream aims to learn more about the specific comparative characteristics of suppressive cell types and to use this knowledge to improve later trial designs and foster novel ideas for new or improved suppressive / tolerogenic cell population.immune response, organ transplant, kidney, clinical trial, cell therapy, clinical, immune system, tool development, basic research, healthcare, drug development, transplant surgery, immunosuppression, hematopoietic immunoregulatory cellSCR_003886(ONE Study, RRID:SCR_003886)European Union FP7related to: University of Regensburg, Bavaria, Germany, King's College London, London, United Kingdom, University of Oxford, Oxford, United Kingdom, Charite - Universitatsmedizin Berlin, Berlin, Germany, Fondazione Centro San Raffaele, Milan, Italy, Loughborough University, Loughborough, United Kingdom, University of Wisconsin-Madison, Wisconsin, USA, University of California at San Francisco, California, USA, Miltenyi Biotec, Electro Scientific Industries, Beckman Coulter, KOEHLER eClinical, Pharmatching, ALTA, listed by: Consortia-pediaLast checked upnlx_158215
Coalition For Accelerating Standards and TherapiesResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceConsortium establishing data standards, tools and methods for conducting research in therapeutic areas important to public health including: Alzheimer's disease, Parkinson's disease, multiple sclerosis, polycystic kidney disease, and tuberculosis. For each therapeutic area, CFAST aims to create the following products: * User/implementation guide * Core data elements with definitions, data types, Biomedical Research Integrated Domain Group (BRIDG)/Study Data Tabulation Model (SDTM) mappings * SDTM domains and examples * Controlled terminology/allowable value sets; along with definitions and data types, all efforts should be made to identify existing work that can be adopted or adapted to meet the requirements before new controlled terminologies or element definitions are developed * Standard CDASH case report forms (CRFs) and SDTM annotations * Examples of Standard for Exchange of Nonclinical Data (SEND) non-clinical data, where appropriate These tools aim to provide a defined and consistent way to collect, store, and submit clinical trial data, allowing researchers to combine and evaluate data from multiple studies using a common approach. In addition to accelerating basic research, these standards also aim to enhance the design of clinical trials and the evaluation of new medical products, such as clinical trial simulation models and methods to evaluate treatment endpoints. All of the tools created by CFAST aim to enable researchers to guide the organization, structure and format of standard clinical trial tabulation datasheets that are submitted to a regulatory authority. Collaborators include the U.S. Food and Drug Administration (FDA), TransCelerate BioPharma and the National Cancer Institute Enterprise Vocabulary Services (NCI-EVS), with participation and input from many Critical Path Institute (C-Path) and Clinical Data Interchange Standards Consortium (CDISC) members as well as other organizations. Any clinical data standards produced under this partnership will be created under the CDISC standards development process, and those standards will then be published openly on the CDISC website as a global CDISC standard.consortium, drug, clinical trial, data element, data sharing, clinical, virologySCR_000206(Coalition For Accelerating Standards and Therapies, RRID:SCR_000206)Critical Path Institute; Arizona; USA FDAlisted by: Consortia-pediaLast checked upnlx_157879
Bio-derived Feedstocks for Sustainable UK-Based Manufacture of Chemicals and Pharmaceutical IntermediatesResource, organization portal, portal, consortium, data or information resourceProject aiming to establish a range of new technologies to enable the synthesis of a range of chemicals from sugar beet pulp (SBP) in a cost-effective and sustainable manner. The chemical and pharmaceutical industries are currently reliant on petrochemical derived intermediates for the synthesis of a wide range of valuable products. Decreasing petrochemical reserves and concerns over costs and greenhouse gas emissions are driving the search for renewable sources of organic synthons. The UK is self-sufficient in the production of SBP which is a by-product of sugar beet production (8 million tonnes grown per year) and processing. The ability to convert SBP into chemicals and pharmaceutical intermediates will therefore have significant economic and environmental benefits. SBP is rich in carbohydrate (nearly 80% by weight) which is made up of roughly equal proportions of 2 biological polymers; cellulose and pectin. To be cost-effective it will be necessary to find uses for each of these substances. The consortium will develop a biorefinery approach for the selective breakdown of both polymers, purification of the breakdown compounds and their use to synthesize a range of added value products such as speciality chemicals, pharmaceuticals and biodegradable polymers. It is already known that cellulose can be broken down into hexose sugars and fermented to ethanol for use in biofuels. The focus is on the release of galacturonic acid and arabinose (from pectin) and their conversion, by chemical or enzymatic means, into added value products. Synthetic Biology methods will also be explored to test the feasibility of metabolically engineering microbial cells to simultaneously breakdown the polymeric feed material and synthesize a desired product, such as aromatic compounds, in a single integrated process. In conducting this research the consortium will adopt a holistic, systems-led, approach to biorefinery design and operation. Computer-based modelling tools will be used to assess the efficiency of raw material, water and energy utilization. Economic and Life Cycle Analysis (LCA) approaches will then be employed to identify the most cost-effective and environmentally benign product and process combinations. The project is supported by a range of industrial partners from raw material producer to intermediate technology providers and end-user chemical and pharmaceutical companies. This is crucial in providing business and socio-economic insights regarding the adoption of renewable resources into their current product portfolios. The company partners will also provide the material and equipment resources for the large-scale verification of project outcomes and their ultimate transition into commercial manufacture. The Intellectual Property (IP) expected to be generated by the consortium will most likely be related to new biocatalysts, synthetic routes, USD devices and modelling software. The data is accessible programmatically using one of three application programming interfaces GtR, GtR-2 and CERIF.chemical, drug, drug development, pharmaceutical, manufacture, product development, sugar beet pulp, sugar beet, polymer, galacturonic acid, arabinose, biorefinery, cellulose, pectin, ethanol, biofuelSCR_000490(Bio-derived Feedstocks for Sustainable UK-Based Manufacture of Chemicals and Pharmaceutical Intermediates, RRID:SCR_000490)University College London; London; United Kingdom EPSRClisted by: Consortia-pediaLast checked upnlx_158450
Biomarkers ConsortiumResource, organization portal, data or information resource, portal, funding resource, consortiumConsortium serving to develop and qualify promising biomarkers in order to help accelerate the delivery of successful new technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease. Current core disease areas of focus include Cancer, Inflammation and Immunity, Metabolic Disorders, and Neuroscience. One of the most difficult tasks facing biomarker assessment and evaluation is harmonizing the approaches of various stakeholders--government, industry, non-profits and foundations, providers, and academic institutions. Consortium founding members and other partners recognize the critical need for a coordinated cross-sector partnership effort. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers. Biomarkers Consortium Goals: * Facilitate the development and qualification of biomarkers using new and existing technologies; * Help qualify biomarkers for specific applications in diagnosing disease, predicting therapeutic response or improving clinical practice; * Generate information useful to inform regulatory decision making; * Make consortium project results broadly available to the entire scientific community.human, biomarker, clinical, translational research, drug development, preventive medicine, medical diagnostics, consortium, biomarker development, neuroscienceSCR_003121(Biomarkers Consortium, RRID:SCR_003121)Foundation for the National Institutes of Health NIH Blueprint for Neuroscience Researchlisted by: Consortia-pediaLast checked upnif-0000-00559
Sage BionetworksResource, organization portal, portal, consortium, data or information resourceA non-profit biomedical research organization developing predictors of disease and accelerating health research through the creation of open systems, incentives, and standards. It was formed to coordinate and link academic and commercial biomedical researchers through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation, and contributor-evolved resources. They challenge the traditional roles of individuals, groups, patients and researchers by redefining how complex biological data is gathered, shared and used. Their mission is to leverage open systems and create new incentives that harness the advances in health care technology, such as computational models to predict outcome and responses to treatment. Their work includes the building of platforms and services and undertaking research developing predictors relating to health. They create technology platforms that facilitate collaboration on data, governance platforms that enable data sharing and reuse, run challenges to solve complex biomedical problems, and perform their own cutting-edge computational biology and research. The ultimate aim is create a culture of open collaboration. Sage Bionetworks accomplishes its work through partnerships and has three primary activities: * Researchers actively collaborate with a number of academic and commercial partners to apply advanced integrative genomic analysis to genetic and clinical datasets. * Provide training for interdisciplinary researchers to gain next generation bioinformatics skills that is the focus of a new National Cancer Institute Center for Cancer Systems Biology. * Catalyzing and coordinating the development of a major new biological network and systems biology resource, the Sage Commons. Their software is available in Github, https://github.com/Sage-Bionetworksbionetwork, medical, research, human, treatment, disease, biological, biomedical, genomic, development, diagnostic, therapeutic, molecular, meta-data, model, clinical, bioinformatics, drug, consortium, data sharing, softwareSCR_003384(Sage Bionetworks, RRID:SCR_003384)Rosetta Inpharmatics Merck Increlated to: GitHub, listed by: Consortia-pediaLast checked upnif-0000-32903
Advanced Immunization TechnologiesResource, organization portal, portal, consortium, data or information resourceA consortium that aims to accelerate the development of immunization technologies for the next generation of human vaccines. The goals are to characterize the mode of action and conduct comparative effectiveness studies of: adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous primeboost schedules, on vaccine efficacy. As part of these clinical trials, the consortium will also investigate the impact of host factors such as age, gender, genetics and pathologies. The consortium hopes to use insights gained from their projects to advance the development of next-generation vaccines, using tools such as standardized animal models to select promising immunization technologies. The intended outcome of this partnership is to improve the vaccine development process by advancing: basic research, new technology development, and clinical trial methods. Scientific objectives: # Development of adjuvants, vectors, formulations, and delivery devices # Selection of candidates, routes of immunization, and prime-boost combinations in animal models # Assessment of the impact of host factors in response to vaccination # Development of concepts and tools from human immunization # Development of concepts and tools to address regulatory and ethical issues posed by novel immunization technologies # Creation of an internationally recognized training program for translational immunology and vaccinology. Data is shared across the research partners within and between the different workstreams. Additionally, the consortium has plans to create a clinical database that combines phenotypic and clinical information to study the immune response to influenza vaccination at a population level, in an effort to advance studies into the effects of genetic background, gender, and disease on vaccine response.drug, consortium, drug development, biomarker, vaccine, immunization, vaccine technology, adjuvant, vector, route, device, prime-boost, host factor, system biology, technology, animal model, human immunology, immunology, phenotype, clinical, clinical trial, public healthSCR_003741(Advanced Immunization Technologies, RRID:SCR_003741)European Union FP7listed by: Consortia-pediaLast checked upnlx_157968
TransCelerate BioPharmaResource, organization portal, portal, consortium, data or information resourceA non-profit research organization aiming to accelerate drug development by increasing the quality and efficiency of clinical studies through the development of shared tools, methods, and platforms. Consortium partnerships are limited to pharmaceutical and biotechnology companies with research & development operations, although there are collaborations with external organizations such the Clinical Data Interchange Standards Consortium (CDISC). Its current focus is to collaborate on: * Standardizing risk-based monitoring * Development of methods to qualify and train clinical trial sites * Development of a common investigator web portal * Development of clinical data standards on efficacy, and methods for comparator drug trials It currently has 5 projects: # Standardized Approach for High-Quality, Risk-Based Monitoring program aims to develop an industry-wide standard and approach for risk-based monitoring of clinical trials in order to enhance patient safety and ensure the quality of clinical trial data. # Shared Site Qualification and Training program aims to standardize GCP training and site qualification credentials in order to realize efficiencies and accelerate study start-up timelines. # Common Investigator Site Portal is a platform designed to streamline investigator and site access through harmonized delivery of content and services. # Data Standards project is a partnership with CDISC to develop industry-wide data standards in priority therapeutic areas to support the exchange and submission of clinical research and meta-data, improving patient safety and outcomes. # Comparator Drugs project aims to establish reliable, rapid sourcing of quality products for use in clinical trials through a comparator supply model enabling accelerated trial timelines and enhanced patient safety.drug, clinical trial, multipharma, data sharing, drug development, consortium, medicine, clinical, standard specificationSCR_003728(TransCelerate BioPharma, RRID:SCR_003728)GlaxoSmithKline, Member companies financial contributions, Member companies in-kind contributionslisted by: Consortia-pediaLast checked upnlx_157913
Observational Medical Outcomes PartnershipResource, organization portal, portal, consortium, data or information resourceInitiative to improve the safety of drugs on the market that utilized information drawn from patient medical record databases and health insurance claims to develop and test methods to detect and evaluate drug safety issues over time. The OMOP pilot project focused on the following objectives: * Defining and evaluating analytical methods that can be used to identify associations between drugs and health-related conditions. * Developing tools for organizing access to and evaluating the usefulness of multiple observational datasets. * Study how information from analyses of observational data can be used to inform ongoing pharmacovigilence efforts. The software tools - packaged as the OMOP Web RL Platform was developed and made available to the public, https://github.com/OMOP . In addition to these data tools, this collaborative research effort discovered methods for using data to reliably identify correlations between individual medical interventions and specific health outcomes. These insights are being used to help inform the FDA Sentinel Initiative as part of the Innovation in Medical Evidence Development and Surveillance (IMEDS) program. The achievements of the program include: * Establishment of a common data model and creation of data characterization tools, and vocabulary mappings * Implementation of Health Outcome of Interest definitions, including a program to implement these definitions as part of the Regularized Identification of Cohorts (RICO) * Release of 14 analysis methods to evaluate the performance of methods and data in identifying drug safety issuesconsortium, drug, drug safety, observational data, claim, electronic medical record, surveillance, prescription medication, health outcome, medical intervention, drug development, safety, common data model, vocabularySCR_003724(Observational Medical Outcomes Partnership, RRID:SCR_003724)Foundation for the National Institutes of Health Biopharmaceutical membersuses: GitHub, listed by: Consortia-pediaLast checked upnlx_157903
Polycystic Kidney Disease Outcomes ConsortiumResource, organization portal, portal, consortium, data or information resourceConsortium to develop evidence supporting the use of imaging Total Kidney Volume (TKV) as a prognostic biomarker that predicts the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to select patients likely to respond to therapy into clinical trials. It aims to replace the currently used measurement of glomerular filtration rate (GFR). Scientists will use the data collected to develop a disease progression model that will evaluate the relationship between TKV and the known complications of ADPKD, including rate of loss of kidney function, hypertension, gross hematuria, kidney stones, urinary tract infections, development of end-stage renal disease, and mortality. These analyses will be used to support the regulatory qualification of TKV as an accepted measure for assessing the progression of ADPKD in clinical trials in which new therapies are tested. PKDOC has the following goals: # Develop standard clinical data elements and definitions that are specific to ADPKD # Create a database of aggregated data from existing multiple, longitudinal, and well-characterized research registries maintained over decades by the leading institutions in ADPKD clinical investigation # Advance and harmonize the missions of regulatory agencies by creating tools that help with the evaluation of new pharmaceutical compounds # Develop a quantitative disease progression model to examine the linkage between TKV and disease outcomesconsortium, drug, imaging, total kidney volume, biomarker, rate, disease progression, imaging biomarker, drug development, kidney volume, kidney, clinical, common data element, therapeutic, clinical trial, standard specification, databaseSCR_003674(Polycystic Kidney Disease Outcomes Consortium, RRID:SCR_003674)Critical Path Institute; Arizona; USA Philanthropic donations, PKD Foundation, U.S. Food and Drug Administrationlisted by: Consortia-pediaLast checked upnlx_157909
BiomarCaREResource, organization portal, portal, consortium, data or information resourceProject to determine the additional value of multiple (new) biomarkers to improve risk estimation of cardiovascular diseases (CVD) related events in Europe and ultimately develop a European biomarker panel for CVD prediction including the classical risk factors and established and novel biomarkers. They will apply small and medium enterprise (SME)-driven technologies and perform large-scale biomarker determination to assess the predictive value of existing and emerging biomarkers. Selection of emerging biomarkers will be based on integrated cutting-edge quantitative proteomic, transcriptomic, metabolomic, and miRNomic datasets established by private and public consortium members that will be disclosed to this consortium. Existing biomarkers will be selected based on non-redundancy and their association with cardiovascular risk and phenotypes. After SME-guided development of innovative assay systems biomarkers will be tested and validated in a stepwise fashion among European populations in primary and secondary prevention. In addition to their impact on risk prediction, their association with lifestyle determinants and cardiovascular phenotypes assessed by ultrasound and MRI technique will be evaluated. A panel will be established which leads to improved disease prediction among different European populations. International collaborations with world-class clinical trial investigators will add data on the interaction of the BiomarCaRE panel with risk-lowering medication and lifestyle changes. The outcome of SME-driven technology development and clinical validation will undergo a medical technology assessment. The determination of cost-effectiveness will guide further clinical evaluation. These studies will reveal new methods of improved cardiovascular risk estimation and will open the path towards personalized medicine.drug, biomarker, diagnostic, cardiovascular risk, phenotype, ultrasound, mri, clinical, epidemiological, risk prediction, lifestyle, risk factor, heartSCR_003841(BiomarCaRE, RRID:SCR_003841)European Union FP7listed by: Consortia-pediaLast checked upnlx_158154
Center for Integration of Medicine and Innovative TechnologyResource, funding resource, organization portal, portal, consortium, data or information resourceA non-profit consortium of Boston academic medical centers and universities (and growing) to accelerate the healthcare innovation cycle by fostering interdisciplinary, inter-institutional collaboration among experts in translational research, medicine, science, engineering, healthcare implementation and entrepreneurship in concert with industry, foundations and government to rapidly improve patient care. It concentrates on early stage, high-risk ideas, projects and supports them through to a commercial exit from academia. It provides innovators with resources to explore, develop and implement novel technological solutions for today's most urgent healthcare problems. CIMIT is dedicated to helping develop medical technology that will help both military and civilian patients.device, procedure, diagnosis, healthcare, consortium, clinical, systems engineering, technology, patient care, translational research, medicine, science, engineering, innovation, consortiumSCR_003710(Center for Integration of Medicine and Innovative Technology, RRID:SCR_003710)Massachusetts Institute of Technology; Massachusetts; USA , Charles Stark Draper Laboratory Membership fees, NIBIB, United States Department of Defenselisted by: Consortia-pediaLast checked upnlx_157880
X
  1. RRID Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  6. Facets

    Here are the facets that you can filter the data by.

  7. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.